To explore the mechanism of perioperative oxycodone exposure on endogenous immunity in patients with esophageal cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078313

Enrollment

Unknown

Registered

2023-12-05

Start date

2023-12-05

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Hydroxycodone group:PCIA: 0.5mg/kg+ 100ml,: 1ml/h,2ml,15min,1 16ml PCIA pump formula: 0.5mg/kg hydroxycodone hydrochloride+100ml sodium chloride injection, parameter setting: infusion rate 1ml/h, sin

Sufentanil group: Sufentanil 2 µ G/kg+sodium chloride injection to 100ml, parameter settings: infusion rate 1ml/h, single dose 2ml, locking time 5min, 1-hour limit of 16ml.

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) Class I-II, age = 75 years old

Exclusion criteria

Exclusion criteria: Patients with severe heart, lung, liver or kidney diseases, hypersensitivity to oxycodone, addiction or abuse of opioid drugs, and dizziness are excluded;

Design outcomes

Primary

Measure	Time frame
T cell;JAK2;	—

Secondary

Measure	Time frame
IL-6;STAT3;	—

Countries

China

Contacts

Public ContactXing Huaixin

Shandong First Medical University Affiliated Cancer Hospital

xinghuaixin521@163.com+86 139 6417 6046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026